Kaohsiung, Taiwan

Hsue-Yin Hsu

This inventor holds 1 USPTO granted patent. Top assignee: We-Win Applied Bio-Tech Co., Ltd.. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hsue-Yin Hsu. Retrieved from https://idiyas.com/inventor/hsue-yin-hsu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hsue-Yin Hsu: Innovator in Antiallergic Treatments

Introduction

Hsue-Yin Hsu is a notable inventor based in Kaohsiung, Taiwan. She has made significant contributions to the field of biotechnology, particularly in the development of antiallergic treatments. Her innovative work focuses on utilizing natural compounds for therapeutic purposes.

Latest Patents

Hsue-Yin Hsu holds a patent for "Compositions and methods of antiallergic phorbol ester and phorbol derivatives as the main active ingredients from the seeds of Aquilaria malaccensis." This invention relates to phorbol esters derived from the seeds of Aquilaria malaccensis, processed through a series of chromatographic techniques. The compositions developed are aimed at treating allergic responses effectively.

Career Highlights

Hsue-Yin Hsu is associated with We-win Applied Bio-tech Co., Ltd., where she continues to advance her research and development efforts. Her work has garnered attention for its potential impact on allergy treatments, showcasing her dedication to improving health outcomes.

Collaborations

Some of her notable coworkers include Fang-Rong Chang and Bing-Hung Chen, who contribute to her research endeavors and collaborative projects.

Conclusion

Hsue-Yin Hsu's innovative work in the field of biotechnology highlights her commitment to developing effective treatments for allergic responses. Her contributions are paving the way for advancements in antiallergic therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…